Partnership between Sonrai and AOA Dx advances speed of ovarian cancer diagnostic test development
In a significant move to advance early and accurate detection of ovarian cancer, Sonrai Analytics and AOA Dx have joined forces in a strategic partnership. The partnership, announced in May 2025, aims to improve the diagnostic landscape for symptomatic women by developing a multi-omic liquid biopsy test [1][3].
Based in Belfast, Sonrai Analytics is an AI-driven precision medicine platform that specialises in biomedical data analysis. AOA Dx, an early-stage biotech company from the US, brings its diagnostic development expertise to the table. This collaboration promises to unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers and enabling earlier and more accurate detection [1][3].
At the heart of this partnership is Sonrai's advanced analytics platform, which will be utilised to integrate and manage AOA's in-house development data, cross-reference it with public datasets, and facilitate seamless analysis within one centralised environment [2]. Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, emphasised the importance of this partnership, stating, "The integration and management of our data within one compliant platform is critical to both our research and regulatory approval process."
The test under development uses a unique combination of novel gangliosides, lipids, and proteins for diagnosis. Sonrai's bioinformatics expertise will enable AOA to harness pre-built machine learning tools and run automated pipelines, further enhancing the accuracy and clinical utility of the test [1].
Prof. Darragh McArt, CEO and Founder of Sonrai Analytics, expressed his enthusiasm for the partnership, stating, "The combination and analysis of multi-omic, clinical, and demographic data within one compliant platform is critical to both AOA Dx's research and regulatory approval process." He added that the partnership has the potential to transform the pathway for women with ovarian cancer, change outcomes, and offer significant savings to healthcare systems.
This collaboration is not Sonrai's first foray into the realm of cancer diagnostics. They also have a partnership with German biotech Plectonic Biotech, focusing on cancer immunotherapies. However, their work with AOA Dx is specifically targeted at ovarian cancer diagnostics [1].
In summary, the strategic partnership between Sonrai Analytics and AOA Dx combines Sonrai’s AI-powered biomedical data analysis with AOA Dx’s diagnostic development expertise to create a novel test for ovarian cancer diagnosis, addressing a critical unmet medical need [1][3]. This collaboration promises to revolutionise the early detection and treatment of ovarian cancer, offering hope for thousands of women worldwide.
References: [1] O'Reilly, A. (2025). Sonrai Analytics and AOA Dx Partner to Develop Novel Ovarian Cancer Diagnostic Test. [online] Available at:
- The partnership between Sonrai Analytics and AOA Dx focuses on developing a novel test for ovarian cancer diagnostics, utilising advanced data and cloud computing technology.
- The collaboration is significant in the Digital Health sector, aiming to revolutionise early detection and treatment of ovarian cancer, especially for symptomatic women.
- The test under development, by combining novel gangliosides, lipids, and proteins for diagnosis, will greatly benefit from Sonrai's bioinformatics expertise in Medical-conditions, specifically cancer, and health-and-wellness.
- This strategic partnership is not Sonrai Analytics' first foray into cancer diagnostics; they also work with Plectonic Biotech on cancer immunotherapies, but their collaboration with AOA Dx is specifically aimed at non-invasive ovarian cancer diagnostics.
